AU2017332789B2 - Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes - Google Patents

Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes Download PDF

Info

Publication number
AU2017332789B2
AU2017332789B2 AU2017332789A AU2017332789A AU2017332789B2 AU 2017332789 B2 AU2017332789 B2 AU 2017332789B2 AU 2017332789 A AU2017332789 A AU 2017332789A AU 2017332789 A AU2017332789 A AU 2017332789A AU 2017332789 B2 AU2017332789 B2 AU 2017332789B2
Authority
AU
Australia
Prior art keywords
rsv
leu
ile
lys
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017332789A
Other languages
English (en)
Other versions
AU2017332789A1 (en
Inventor
Ursula J. Buchholz
Peter L. Collins
Cyril LENOUEN
Steffen Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Codagenix Inc
US Department of Health and Human Services
Original Assignee
Usa As Represented By Secretary
Codagenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usa As Represented By Secretary, Codagenix Inc filed Critical Usa As Represented By Secretary
Publication of AU2017332789A1 publication Critical patent/AU2017332789A1/en
Application granted granted Critical
Publication of AU2017332789B2 publication Critical patent/AU2017332789B2/en
Priority to AU2021218112A priority Critical patent/AU2021218112B2/en
Priority to AU2022256195A priority patent/AU2022256195B2/en
Priority to AU2024203948A priority patent/AU2024203948A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00061—Methods of inactivation or attenuation
    • C12N2760/00062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2017332789A 2016-09-23 2017-09-22 Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes Active AU2017332789B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2021218112A AU2021218112B2 (en) 2016-09-23 2021-08-19 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2022256195A AU2022256195B2 (en) 2016-09-23 2022-10-21 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2024203948A AU2024203948A1 (en) 2016-09-23 2024-06-11 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662399133P 2016-09-23 2016-09-23
US62/399,133 2016-09-23
US201662400476P 2016-09-27 2016-09-27
US62/400,476 2016-09-27
PCT/US2017/053047 WO2018057950A1 (en) 2016-09-23 2017-09-22 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021218112A Division AU2021218112B2 (en) 2016-09-23 2021-08-19 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes

Publications (2)

Publication Number Publication Date
AU2017332789A1 AU2017332789A1 (en) 2019-05-09
AU2017332789B2 true AU2017332789B2 (en) 2021-05-27

Family

ID=60009756

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2017332789A Active AU2017332789B2 (en) 2016-09-23 2017-09-22 Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
AU2021218112A Active AU2021218112B2 (en) 2016-09-23 2021-08-19 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2022256195A Active AU2022256195B2 (en) 2016-09-23 2022-10-21 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2024203948A Pending AU2024203948A1 (en) 2016-09-23 2024-06-11 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2021218112A Active AU2021218112B2 (en) 2016-09-23 2021-08-19 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2022256195A Active AU2022256195B2 (en) 2016-09-23 2022-10-21 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2024203948A Pending AU2024203948A1 (en) 2016-09-23 2024-06-11 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes

Country Status (5)

Country Link
US (4) US10808012B2 (enExample)
EP (1) EP3515930A1 (enExample)
JP (3) JP7198759B2 (enExample)
AU (4) AU2017332789B2 (enExample)
WO (1) WO2018057950A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9957486B2 (en) 2013-02-08 2018-05-01 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
EP3515930A1 (en) 2016-09-23 2019-07-31 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
RU2020124143A (ru) 2017-12-22 2022-01-24 Кодадженикс Инк. Рекомбинантный вирус с областью деоптимизированной пары кодонов и его применение для лечения рака
BR112020018188A2 (pt) 2018-03-08 2021-02-02 Codagenix Inc. flavivírus atenuados
CA3178538A1 (en) 2020-05-13 2021-11-18 Peter L. Collins Rsv vaccine bearing one or more p gene mutations
EP4181956A4 (en) * 2020-07-16 2024-08-07 Griffith University VACCINE AGAINST A LIVE ATTENUATED VIRUS
MX2023011784A (es) * 2021-04-08 2023-10-11 Codagenix Inc Metodo para provocar una respuesta inmunitaria contra virus sincitial respiratorio.
WO2025054424A1 (en) * 2023-09-06 2025-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human parainfluenza virus immunogenic molecules
WO2025128971A1 (en) * 2023-12-14 2025-06-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rsv vaccine bearing a polynucleotide which is de-optimised and de-attenuated

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150368622A1 (en) * 2013-02-08 2015-12-24 The United Of America, As Represented By Secretary, Department Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224404A1 (de) 1982-06-30 1984-01-05 LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl Reibungskupplung sowie verfahren zu deren montage
CA2230033C (en) 1995-09-27 2010-01-26 Peter L. Collins Production of infectious respiratory syncytial virus from cloned nucleotide sequences
EP2112220A3 (en) 1996-07-15 2010-01-06 The Government of the United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
BR9809456B1 (pt) 1997-05-23 2011-06-28 molécula isolada de polinucleotìdeo, composição de célula ou isenta de célula, partìcula de piv infeciosa, atenuada e imunogênica, e, composição imunogênica.
CN100491530C (zh) 1999-04-13 2009-05-27 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒嵌合呼吸道合胞病毒疫苗
AU2002223275A1 (en) 2000-11-22 2002-06-03 Biota Scientific Management Pty Ltd A method of expression and agents identified thereby
US7297786B2 (en) 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
EP3312272B1 (en) 2004-10-08 2019-08-28 The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services Modulation of replicative fitness by using less frequently used synonymous codons
EP3431099B1 (en) 2007-03-30 2024-01-03 The Research Foundation for The State University of New York Attenuated viruses useful for vaccines
RU2011122615A (ru) 2008-11-05 2012-12-20 Мерк Шарп Энд Домэ Корп. Живой аттенуированный респираторно-синцитиальный вирус
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
EP3515930A1 (en) 2016-09-23 2019-07-31 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150368622A1 (en) * 2013-02-08 2015-12-24 The United Of America, As Represented By Secretary, Department Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C. LE NOUEN ET AL, "Attenuation of human respiratory syncytial virus by genome-scale codon-pair deoptimization", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, US, (2014-08-25), vol. 111, no. 36, pages 13169 - 13174 *

Also Published As

Publication number Publication date
US20190233476A1 (en) 2019-08-01
WO2018057950A1 (en) 2018-03-29
JP7198759B2 (ja) 2023-01-04
US12054519B2 (en) 2024-08-06
EP3515930A1 (en) 2019-07-31
AU2022256195B2 (en) 2024-03-14
JP2022188047A (ja) 2022-12-20
AU2022256195A1 (en) 2023-02-02
AU2024203948A1 (en) 2024-07-04
JP7573001B2 (ja) 2024-10-24
JP2019534709A (ja) 2019-12-05
US20240417431A1 (en) 2024-12-19
AU2021218112B2 (en) 2022-07-21
US20210188920A1 (en) 2021-06-24
AU2021218112A1 (en) 2021-09-09
US10808012B2 (en) 2020-10-20
AU2017332789A1 (en) 2019-05-09
JP2025020142A (ja) 2025-02-12
US20220340619A1 (en) 2022-10-27
US11390651B2 (en) 2022-07-19

Similar Documents

Publication Publication Date Title
AU2021218112B2 (en) Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
AU2020203460B2 (en) Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
JP7357709B2 (ja) さまざまな弱毒化表現型をもたらすｍ２－２ ｏｒｆにおける突然変異を含む組換えｒｓウイルス株
US11918638B2 (en) Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts
CN116348594A (zh) 携带一个或多个p基因突变的rsv疫苗
RU2773746C2 (ru) Рекомбинантные штаммы респираторно-синцитиального вируса с мутациями в м2-2 orf, обеспечивающими диапазон аттенуирующих фенотипов

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)